📉 The Financial Deep Dive
Global Health Limited (Medanta) showcased robust top-line expansion in its Q3 FY2026 results, with total income surging 19.1% year-on-year (YoY) to INR 11,428 million. This growth was underpinned by a significant uptick in patient volumes, reporting 14.3% YoY growth in in-patients and 19.5% YoY growth in out-patients. Average Revenue Per Occupied Bed (ARPOB) also saw a healthy increase of 9.9% YoY, indicating improved service realization.
However, the company's consolidated profitability faced headwinds. The newly commissioned Medanta Noida hospital, while contributing INR 343 million in revenue for the quarter, incurred an EBITDA loss of INR 320 million due to initial operating expenses, depreciation, and finance costs. This new facility's startup impact led to a 1.7% YoY decline in consolidated EBITDA to INR 2,494 million. Excluding Noida, the core business demonstrated strong operational performance, with EBITDA growing by a healthy 10.9% YoY to INR 2,814 million.
Profit After Tax (PAT) saw a significant YoY decrease of 33.5% to INR 950 million for Q3 FY2026. This was further exacerbated by a non-recurring exceptional item of INR 366 million, stemming from the statutory impact of new Labour Codes. For the nine-month period, PAT grew 8.5% YoY to INR 4,124 million.
The Grill & Outlook:
Management expressed confidence in building a strong foundation for future growth, citing patient volumes and improved realisations as key drivers. However, the initial operating losses from the Noida facility are a near-term concern for consolidated margins. The impact of new labour codes, leading to an exceptional item, highlights potential regulatory cost exposures. Notably, the company did not provide specific forward-looking guidance figures, leaving the Street to assess the ramp-up trajectory of Noida and its eventual contribution to profitability.
🚩 Risks & Outlook
The primary risks revolve around the speed and efficiency of the Noida hospital's ramp-up and its ability to achieve profitability. Execution risks in expanding capacity across other facilities (Patna, Ranchi) also remain. The impact of the new Labour Codes, as evidenced by the exceptional item, could lead to ongoing compliance costs or further adjustments. Investors will be closely watching the margin trajectory in the coming quarters, particularly the extent to which the Noida facility's losses are offset by the strong performance of mature and developing hospitals.